Press Releases
Date picker
Category
Results per page
Kancera provides an update on the development of the company’s pharmaceutical project and nominates a new drug candidate
Regulatory
two thirds of patients have now been dosed in the clinical study of KAND567 for the treatment of COVID-19; patient recruitment is expected to be completed during the current quarter,successful…
Pioneering research results for Kancera’s Fractalkine blockers may pave the way for new treatment for ovarian cancer
Kancera AB (Nasdaq First North Premier Growth Market: KAN) reports preclinical research results, which show that the company's Fractalkine blockers have the potential to disrupt cancer cells' resistance to chemotherapy…
Interim report for fourth quarter 2020, 1 January – 31 December 2020
Fourth quarter in brief as well as the period 1 January – 31 December 2020Net sales for the period (January to December) amounted to SEK 0,1 million (3,2 million), of…
Kancera provides update on successful phase I study and planned phase II study with KAND567 treatment following heart attack
This is a translation of a press release in Swedish published December 29, 2020
Kancera appoints a Scientific Advisory Board with leading scientists in cardiology and immunology
This is a translation of a press release in Swedish published December 21, 2020
Agreement on development of HDAC6 inhibitors discontinued.
Kancera AB announces today that the pharmaceutical company Grünenthal GmbH has chosen to terminate the parties' research and option agreement. Since the end of 2018, Grünenthal has been responsible for…
Interim report for the third quarter 2020, January 1st – September 30th, 2020
Third quarter in brief as well as the period 1 January – 30 September 2020Net sales for the period (January to September) amounted to SEK 0,09 million (3,3 million), of…
Kancera starts study in covid-19 patients
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that screening of covid-19 patients for the clinical phase II study of KAND567 starts today. The study, which is carried…
Interim report for the second quarter 2020. January 1st – June 30th, 2020
Regulatory
Second quarter in briefand the period 1 January – 30 June 2020 Net sales for the period (January to June) amounted to SEK 2,6 million (3,1 million), of which…
Fraktalkine pathway mechanism of action for Kancera drug candidate KAND567 is linked to reduced risk of serious complications in COVID-19
Preparation for a clinical study with KAND567 in COVID-19 patients now under way Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that independent researchers have published results…